Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Experimental and Molecular Therapeutics 34: Genes, Drugs, and Novel Agents

ERRP is downregulated in colon cancer, and is a potential anti-tumor agent.

Edi Levi, Ramzi M. Mohammad, Richard Jaszewski, Udayini Kodali, Dorota Marciniak, Paula Sochacki, Arun K. Rishi and Adhip P. Majumdar
Edi Levi
VA Med Ctr/Wayne State University, Detroit, MI and Karmanos Cancer Institute/Wayne State University, Detroit, MI.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ramzi M. Mohammad
VA Med Ctr/Wayne State University, Detroit, MI and Karmanos Cancer Institute/Wayne State University, Detroit, MI.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard Jaszewski
VA Med Ctr/Wayne State University, Detroit, MI and Karmanos Cancer Institute/Wayne State University, Detroit, MI.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Udayini Kodali
VA Med Ctr/Wayne State University, Detroit, MI and Karmanos Cancer Institute/Wayne State University, Detroit, MI.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dorota Marciniak
VA Med Ctr/Wayne State University, Detroit, MI and Karmanos Cancer Institute/Wayne State University, Detroit, MI.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paula Sochacki
VA Med Ctr/Wayne State University, Detroit, MI and Karmanos Cancer Institute/Wayne State University, Detroit, MI.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Arun K. Rishi
VA Med Ctr/Wayne State University, Detroit, MI and Karmanos Cancer Institute/Wayne State University, Detroit, MI.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Adhip P. Majumdar
VA Med Ctr/Wayne State University, Detroit, MI and Karmanos Cancer Institute/Wayne State University, Detroit, MI.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published April 2004
  • Article
  • Info & Metrics
Loading
Proc Amer Assoc Cancer Res, Volume 45, 2004

Abstract

3791

EGF-Receptor Related Protein (ERRP), a novel “negative regulator” of EGFR, possesses ∼90% homology to the extracellular domain of the receptor. ERRP binds EGFR ligands forming inactive heterodimers leading to inhibition of EGFR signaling. Here, we examined ERRP expression in benign colon, tubular adenomas and adenocarcinomas. We also investigated in vitro and in vivo effects of ERRP on tumor growth. SCID mice were xenotransplanted with colon cancer HCT-116 cells and treated with recombinant ERRP or vehicle. For in vitro studies, HCT-116 cells were exposed to recombinant ERRP or vehicle, followed by determination of cell cycle and apoptosis. 35 cases of colonic adenocarcinoma and 10 adenomatous polyps were examined with anti-ERRP antibodies. Normal colonic mucosa demonstrated strong supranuclear and membranous staining for ERRP. The tumors showed a diffused cytoplasmic staining which was inversely associated with tumor grade. The staining score was significantly lower in the high-grade carcinoma compared to well-differentiated carcinomas; the intramucosal carcinomas displayed weaker staining. Low-grade dysplastic adenomas retained strong staining when compared with the high grade dysplastic areas. Exposure of HCT-116 cells to recombinant ERRP demonstrated a G0/G1 arrest and increased apoptosis. ERRP treatment of SCID mice bearing HCT-116 derived tumors showed significant tumor growth retardation. The apoptotic rate in the ERRP treated tumor was significantly higher than the controls, as evidenced by reduced phospho-Akt and elevated levels of activated caspase 3. In addition, MAP kinase activation was down-regulated in ERRP treated tumors. In conclusion, ERRP is differentially expressed in colonic adenocarcinomas, with diminished expression in high-grade carcinomas. ERRP causes apoptosis and cell cycle arrest and tumor growth delay in vivo. We propose that ERRP is a potential therapeutic agent for colorectal cancer.

  • American Association for Cancer Research
Previous
Back to top
April 2004
Volume 64, Issue 7 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
ERRP is downregulated in colon cancer, and is a potential anti-tumor agent.
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
ERRP is downregulated in colon cancer, and is a potential anti-tumor agent.
Edi Levi, Ramzi M. Mohammad, Richard Jaszewski, Udayini Kodali, Dorota Marciniak, Paula Sochacki, Arun K. Rishi and Adhip P. Majumdar
Cancer Res April 1 2004 (64) (7 Supplement) 875;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
ERRP is downregulated in colon cancer, and is a potential anti-tumor agent.
Edi Levi, Ramzi M. Mohammad, Richard Jaszewski, Udayini Kodali, Dorota Marciniak, Paula Sochacki, Arun K. Rishi and Adhip P. Majumdar
Cancer Res April 1 2004 (64) (7 Supplement) 875;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Pre-clinical efficacy, pharmacokinetic, and toxicity studies of AGRO100, an anti-tumor oligonucleotide aptamer.
  • Growth inhibition of squamous carcinoma cells by suppression of cyclin D1 using small interfering RNA.
  • Analysis of downstream gene expression changes following thymidylate synthase downregulation by antisense oligodeoxynucleotides.
Show more Experimental and Molecular Therapeutics 34: Genes, Drugs, and Novel Agents
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement